NCT00452634View on ClinicalTrials.gov

Irinotecan/Cisplatin Plus Simvastatin in Extensive Disease-Small Cell Lung Cancer (ED-SCLC)

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

November 30, 2009

Study Completion Date

May 31, 2010

Conditions
Small Cell Lung Cancer
Interventions
DRUG

Irinotecan

Irinotecan 65mg/m2/iv over 90min on day 1 and 8, repeat Q 3weeks. until disease progression, unacceptable toxicity or patients' refusal.

DRUG

Cisplatin

Cisplatin 30mg/m2/iv over 30min on day 1 and 8, repeat Q 3weeks. until disease progression, unacceptable toxicity or patients' refusal.

DRUG

Simvastatin

simvastatin 40mg/QD, PO, daily, every 3 weeks

Trial Locations (1)

411-769

National Cancer Center, Korea, Goyang-si

All Listed Sponsors
lead

National Cancer Center, Korea

OTHER_GOV

NCT00452634 - Irinotecan/Cisplatin Plus Simvastatin in Extensive Disease-Small Cell Lung Cancer (ED-SCLC) | Biotech Hunter | Biotech Hunter